Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal safety of 6 mg ibandronate IV over 15 minutes in metastatic breast cancer with bone disease
2005-000535-18Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibandronic acid in breast cancer and bone metastases, sponsored by Roche. Primary endpoint: Renal safety based on serum creatinine increase. Started Dec 2005; status: completed.
02
Drugs
ibandronic acid
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on 2005-000535-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000535-18.